Insightec MR-Guided Focused Ultrasound Technology Recommended for National Coverage for Dutch Patients Living with Essential Tremor

The Netherlands is the latest European country to recommend national coverage for the treatment of essential tremor with focused ultrasound.


Insightec, a pioneer and global leader in focused ultrasound, has welcomed a positive recommendation report[1] from the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) to have MR-guided focused ultrasound (MRgFUS) reimbursed for people suffering from essential tremor (ET). This recommendation is a pivotal moment, paving the way for nation-wide access to focused ultrasound treatment for essential tremor.

ZIN Recommendation

Released to the public on the public on December 18, 2023, the ZIN recommendation concludes that MRgFUS (also called high-intensity focused ultrasound, or HIFU) which was pioneered by Insightec, is an effective treatment for patients with moderate to severe medication-refractory essential tremor who are not suitable for deep brain stimulation. It also concludes that these patients should therefore be included in the national basic health insurance package, which would guarantee patient access to the therapy. The report was produced following a request submitted by Amsterdam UMC in early 2023 with the support of Dutch medical societies, including the Dutch Association for Neurosurgery (NVvN) and the Dutch Association for Neurology (NVN).

“This is an important day not only for us at Insightec, but also for over 17 million Dutch residents who could not have access to focused ultrasound treatment for essential tremor so far,” says Maurice Ferré, M.D., CEO and chairman of the board of Insightec. “We are delighted to welcome the Netherlands in the growing club of countries that secure patient access to MRgFUS.”

Significant Reductions in Upper Limb Tremor

According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.[2]

About MRgFUS. MR-guided focused ultrasound (MRgFUS), an effective, non-invasive treatment option for essential tremor. MRgFUS uses specialised ultrasound technology to deliver targeted brain therapy without an incision to ablate the brain tissue that causes abnormal movements. Guided by MRI to target the specific area of the brain, neurosurgeons benefit from real-time, detailed images of the brain for precise localisation and monitoring during the procedure.

About Essential Tremor. Essential tremor (ET) is the most common movement disorder[3]. It is characterized by an isolated upper limb action tremor of at least three years’ duration without other neurological signs, although some patients may exhibit a range of other symptoms and signs.

[2] MSAC Public Summary Document. Application No. 1614 – Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor. Insightec Ltd. Available at$File/1614%20Final%20PSD%20-%20Mar-Apr%202021_redacted.pdf (accessed August 2023)
[3] Louis ED, McCreary M. How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor. Tremor and Other Hyperkinetic Movements. 2021; 11(1): 28, pp. 1–14. DOI:

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“Working closely with leading interventionists, we designed the latest Azurion neuro biplane to meet their requirements of superior patient care, optimized angio suite performance, and efficient return on investment.  Together, I am confident we can continue to reduce the impact of stroke, helping more patients to recover faster and reducing long-term impact on their health," said Mark Stoffels, Business Leader of Image Guided Therapy Systems at Philips.
LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy